Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

The latest 13F from Affinity Asset Advisors, LLC covers Q2 2026 (filed Aug 13, 2026): 104 long positions worth $2.04B. The top 10 holdings make up 42.6% of the portfolio, and the largest is Roivant Sciences Ltd. (ROIV) at 6.5%. Livermore has 23 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
17
Est. +$115.3M
Added
32
Est. +$250.9M
Reduced
30
Est. −$215.3M
Sold out
8
Est. −$159.3M

Top 5 holdings

Share of this quarter's portfolio value

  1. ROIVRoivant Sciences Ltd.
    6.5%$132.7MHistory
  2. APGEApogee Therapeutics, Inc.
    6.4%$131.0MHistory
  3. SYRESpyre Therapeutics, Inc.
    5.6%$113.6MHistory
  4. XENEXenon Pharmaceuticals Inc.
    4.7%$96.3MHistory
  5. ERASErasca, Inc.
    4.7%$96.2MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. TRAXFirst Tracks Biotherapeutics, Inc.
    +$40.9MNewHistory
  2. ROIVRoivant Sciences Ltd.
    +$33.6MAddedHistory
  3. AVTXAvalo Therapeutics, Inc.
    +$28.8MAddedHistory
  4. RVMDRevolution Medicines, Inc.
    +$28.1MAddedHistory
  5. INSMINSMED Inc
    +$18.1MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. TRAXFirst Tracks Biotherapeutics, Inc.
    +2.00 pp0.0% → 2.0%History
  2. ROIVRoivant Sciences Ltd.
    +1.94 pp4.5% → 6.5%History
  3. RVMDRevolution Medicines, Inc.
    +1.72 pp0.6% → 2.3%History
  4. AVTXAvalo Therapeutics, Inc.
    +1.45 pp1.2% → 2.6%History
  5. ORKAOruka Therapeutics, Inc.
    +1.31 pp1.4% → 2.7%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CNTACentessa Pharmaceuticals plc
    −$55.6MSold outHistory
  2. ACLXArcellx, Inc.
    −$41.7MSold outHistory
  3. APGEApogee Therapeutics, Inc.
    −$39.5MReducedHistory
  4. TEVATeva Pharmaceutical Industries Ltd
    −$34.8MReducedHistory
  5. TERNTerns Pharmaceuticals, Inc.
    −$29.7MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CNTACentessa Pharmaceuticals plc
    −3.26 pp3.3% → 0.0%History
  2. ACLXArcellx, Inc.
    −2.44 pp2.4% → 0.0%History
  3. TEVATeva Pharmaceutical Industries Ltd
    −1.85 pp2.5% → 0.6%History
  4. TERNTerns Pharmaceuticals, Inc.
    −1.74 pp1.7% → 0.0%History
  5. XENEXenon Pharmaceuticals Inc.
    −1.00 pp5.7% → 4.7%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$2.04B
+$339.7M (+19.9%) vs. prior quarter
Positions
104
+9 vs. prior quarter
Top 10 concentration
42.6%
Top 10 as share of value
Turnover
19.5%
Q2 2026, one quarter
Average holding period
7.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $2.04B (Q2 2026)

Q1 2021: $204.0MQ2 2021: $209.9MQ3 2021: $251.2MQ4 2021: $234.4MQ1 2022: $252.2MQ2 2022: $182.6MQ3 2022: $216.9MQ4 2022: $218.2MQ1 2023: $260.2MQ2 2023: $254.1MQ3 2023: $306.1MQ4 2023: $501.5MQ1 2024: $615.1MQ2 2024: $634.9MQ3 2024: $644.5MQ4 2024: $640.1MQ1 2025: $638.8MQ2 2025: $676.3MQ3 2025: $1.07BQ4 2025: $1.39BQ1 2026: $1.71BQ2 2026: $2.04B
Q1 2021Q2 2026
13F filings of Affinity Asset Advisors, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 13, 2026104$2.04BROIVAPGESYREvs. Q1 2026SEC
Q1 2026May 14, 202695$1.71BAPGEXENEERASvs. Q4 2025SEC
Q4 2025Feb 13, 202686$1.39BAPGEINSMABVXvs. Q3 2025SEC
Q3 2025Nov 13, 202586$1.07BVRNAINSMSPYvs. Q2 2025SEC
Q2 2025Aug 13, 202577$676.3MVRNAINSMXENEvs. Q1 2025SEC
Q1 2025May 14, 202581$638.8MXENEAPGEVRNAvs. Q4 2024SEC
Q4 2024Feb 13, 202575$640.1MXENEAPGEACLXvs. Q3 2024SEC
Q3 2024Nov 13, 202477$644.5MXENEAPGENUVLvs. Q2 2024SEC
Q2 2024Aug 14, 202486$634.9MXENEAPGEMDGLvs. Q1 2024SEC
Q1 2024May 14, 202477$615.1MAPGEXENEMDGLvs. Q4 2023SEC
Q4 2023Feb 13, 202473$501.5MIMGNCERECBAYvs. Q3 2023SEC
Q3 2023Nov 14, 202369$306.1MAPGETEVACBAYvs. Q2 2023SEC
Q2 2023Aug 21, 2023Amended62$254.1MMDGLCEREESTAvs. Q1 2023SEC
Q1 2023May 15, 202363$260.2MKDNYMDGLRXDXvs. Q4 2022SEC
Q4 2022Feb 13, 202354$218.2MKDNYMDGLESTAvs. Q3 2022SEC
Q3 2022Nov 14, 202247$216.9MESTAKDNYGBTvs. Q2 2022SEC
Q2 2022Aug 12, 202240$182.6MESTAKURAKDNYvs. Q1 2022SEC
Q1 2022May 13, 202248$252.2MNARIMORFKURAvs. Q4 2021SEC
Q4 2021Feb 11, 202246$234.4MMORFSWTXVINCvs. Q3 2021SEC
Q3 2021Nov 12, 202166$251.2MBBIOVINCMORFvs. Q2 2021SEC
Q2 2021Aug 13, 202162$209.9MBBIOMORFVINCvs. Q1 2021SEC
Q1 2021May 14, 202162$204.0MBBIOMORFCRIS–SEC

13D and 13G filings

Companies where Affinity Asset Advisors, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

13 companies, largest stake first.

Companies where Affinity Asset Advisors, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
IBIOiBio, Inc.13G/A9.99%5.07M shares0.00 ppfrom 9.99%Aug 26, 20255 filingsAug 13, 2026SEC
KPTIKaryopharm Therapeutics Inc.13G/A8.60%2.07M shares0.00 ppfrom 8.60%Apr 10, 20253 filingsMay 14, 2026SEC
LXEOLexeo Therapeutics, Inc.13G/A8.40%6.67M shares+1.30 ppfrom 7.10%Jun 4, 20253 filingsAug 13, 2026SEC
OVIDOvid Therapeutics Inc.13G/A7.90%15.1M shares−1.20 ppfrom 9.10%Dec 18, 20254 filingsAug 13, 2026SEC
HLXCHelix Acquisition Corp. III13G7.00%1.25M sharesNewMay 14, 20261 filingMay 14, 2026SEC
EQEquillium, Inc.13G6.50%4.10M sharesNewAug 13, 20261 filingAug 13, 2026SEC
STROSutro Biopharma, Inc.13G/A6.50%1.07M shares−2.30 ppfrom 8.80%Oct 23, 20253 filingsMay 14, 2026SEC
NXTCNextCure, Inc.13G/A6.40%274.1K shares−3.59 ppfrom 9.99%Jun 27, 20245 filingsAug 13, 2026SEC
TRAXFirst Tracks Biotherapeutics, Inc.13G5.80%2.03M sharesNewAug 13, 20261 filingAug 13, 2026SEC
FBRXForte Biosciences, Inc.13G/A5.60%1.15M shares−1.70 ppfrom 7.30%Dec 23, 20254 filingsAug 13, 2026SEC
AVTXAvalo Therapeutics, Inc.13G/A5.50%2.90M shares0.00 ppfrom 5.50%Dec 31, 20245 filingsAug 13, 2026SEC
VRCAVerrica Pharmaceuticals Inc.13G/A5.50%884.2K shares+0.03 ppfrom 5.47%Dec 3, 20252 filingsJan 29, 2026SEC
AMANAmanat Acquisition Corp.13G5.00%375.0K sharesNewAug 13, 20261 filingAug 13, 2026SEC

Latest filings

53 filings on file made by Affinity Asset Advisors, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Affinity Asset Advisors, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
LXEOLexeo Therapeutics, Inc.Aug 13, 20264:12 PM ET13G/A8.40%6.67M shares+1.30 ppfrom 7.10%Jun 30, 2026SEC
EQEquillium, Inc.Aug 13, 20264:11 PM ET13G6.50%4.10M sharesNewJun 30, 2026SEC
AMANAmanat Acquisition Corp.Aug 13, 20264:10 PM ET13G5.00%375.0K sharesNewJun 30, 2026SEC
TRAXFirst Tracks Biotherapeutics, Inc.Aug 13, 20264:09 PM ET13G5.80%2.03M sharesNewJun 30, 2026SEC
FBRXForte Biosciences, Inc.Aug 13, 20264:08 PM ET13G/A5.60%1.15M shares−1.70 ppfrom 7.30%Jun 30, 2026SEC
OVIDOvid Therapeutics Inc.Aug 13, 20264:07 PM ET13G/A7.90%15.1M shares−1.20 ppfrom 9.10%Jun 30, 2026SEC
AVTXAvalo Therapeutics, Inc.Aug 13, 20264:06 PM ET13G/A5.50%2.90M shares0.00 ppfrom 5.50%Jun 30, 2026SEC
IBIOiBio, Inc.Aug 13, 20264:05 PM ET13G/A9.99%5.07M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
NXTCNextCure, Inc.Aug 13, 20264:05 PM ET13G/A6.40%274.1K shares−3.59 ppfrom 9.99%Jun 30, 2026SEC
OVIDOvid Therapeutics Inc.May 14, 20264:17 PM ET13G/A9.10%15.6M shares+0.10 ppfrom 9.00%Mar 31, 2026SEC
FBRXForte Biosciences, Inc.May 14, 20264:15 PM ET13G/A7.30%1.01M shares+0.60 ppfrom 6.70%Mar 31, 2026SEC
VTYXVentyx Biosciences, Inc.May 14, 20264:14 PM ET13G/A0.00%0 shares−9.00 ppfrom 9.00%Below 5%Mar 31, 2026SEC
STROSutro Biopharma, Inc.May 14, 20264:13 PM ET13G/A6.50%1.07M shares−2.30 ppfrom 8.80%Mar 31, 2026SEC
IBIOiBio, Inc.May 14, 20264:11 PM ET13G/A9.99%3.49M shares0.00 ppfrom 9.99%Mar 31, 2026SEC
AVTXAvalo Therapeutics, Inc.May 14, 20264:09 PM ET13G/A5.50%1.34M shares−0.20 ppfrom 5.70%Mar 31, 2026SEC
HLXCHelix Acquisition Corp. IIIMay 14, 20264:08 PM ET13G7.00%1.25M sharesNewMar 31, 2026SEC
KPTIKaryopharm Therapeutics Inc.May 14, 20264:05 PM ET13G/A8.60%2.07M shares0.00 ppfrom 8.60%Mar 31, 2026SEC
NXTCNextCure, Inc.Jan 29, 20269:33 PM ET13G/A9.99%348.6K shares+2.82 ppfrom 7.17%Jan 22, 2026SEC
KPTIKaryopharm Therapeutics Inc.Jan 29, 20269:32 PM ET13G/A8.60%1.71M shares+0.77 ppfrom 7.83%Jan 22, 2026SEC
IBIOiBio, Inc.Jan 29, 20269:29 PM ET13G/A9.99%2.40M shares0.00 ppfrom 9.99%Jan 22, 2026SEC